Industry Overview - The isoprene rubber industry in China has rapidly developed since achieving industrial production in 2010, becoming the world's second-largest producer and the largest producer of rare earth-based polyisoprene rubber [1][10] - In the first five months of 2025, China's isoprene rubber production was 25,100 tons, a year-on-year decrease of 4.41%, while consumption was 21,100 tons, down 13.51% year-on-year [10][12] - The traditional downstream tire industry is facing demand slowdowns due to the lightweight trend of new energy vehicles, while consumption in non-tire sectors like construction and footwear is also weak [10][12] Industry Development History - The development of China's isoprene rubber industry can be divided into three stages: the initial stage before 2010, the industrial breakthrough stage from 2010 to 2018, and the structural adjustment stage from 2019 to the present [4][5] - The first industrial production facility for rare earth isoprene rubber was established in 2010, ending the history of no industrial production in China [4][5] - Since 2019, the industry has entered an adjustment period with declining capacity utilization and increased industry concentration [5][6] Industry Chain - The upstream of the isoprene rubber industry includes raw materials such as isoprene monomer, catalysts, and solvents, as well as production equipment [8] - The midstream involves the production and manufacturing of isoprene rubber, while the downstream applications include tires, medical materials, and various industrial products [8] Current Industry Status - The industry is currently experiencing a decline in demand and production, with a significant drop in consumption in traditional sectors [10][12] - The import of isoprene rubber surged to 56,100 tons in the first four months of 2025, a year-on-year increase of 102.73%, while exports increased by 10.55% to 13,800 tons [16] Key Enterprises - Major players in the industry include Sinopec Yanshan Petrochemical, which produces high-end products with a cis-structure content of 95%-98%, and Huizhou Yikeshi, which has a production capacity of 500,000 tons per year [18][19] - Xinjiang Tianli Petrochemical focuses on deep processing of carbon five and carbon nine, with an isoprene rubber production capacity of 30,000 tons per year [21][19] Industry Development Trends - The industry is expected to focus on product structure upgrades and high-end development, with an emphasis on reducing reliance on imports for high-end applications [25][26] - Emerging applications in the pharmaceutical sector are anticipated to drive demand growth, as isoprene rubber is increasingly used in medical packaging and components [27] - An export-oriented development pattern is expected to emerge as domestic demand growth is limited, with the "Belt and Road" initiative enhancing international competitiveness [28]

Core Viewpoint - The company is focused on high-quality development, emphasizing the production of petroleum resins and polypropylene while enhancing its industrial chain and product value [2] Group 1: Future Development Strategy - The company aims to achieve sustainable development by improving its core competitiveness and product value through technological innovation and industry upgrades [2] - The company is committed to integrating raw material resources and extending its industrial chain to enhance its competitive edge [2] Group 2: Shareholder Management and Competition - The controlling shareholder actively incorporates market value management into performance assessments, using indicators such as stock price comparisons and investor relations metrics [3] - There is no competition between the company and its controlling shareholder, China National Petroleum Corporation Daqing Petrochemical Co., Ltd. [4] Group 3: Research and Development - The company has optimized its R&D projects based on market trends and customer feedback, leading to a reduction in R&D personnel [5] - A dedicated project department has been established with six specialized R&D staff to explore new product areas [5] Group 4: Policy Impact and Operational Strategy - The company is not significantly affected by the "anti-involution" policy due to stable raw material supply and customer relationships [6] - The company plans to enhance operational efficiency and profitability through technological innovation and product quality improvements [6] Group 5: New Energy and New Materials Initiatives - In 2024, the company launched a 10,800-ton/year butadiene extraction facility, which began production in October 2024 [8] - A project to upgrade the isoprene hydrogenation facility is planned for 2025, aiming to increase capacity to 35,000 tons/year [8][9] Group 6: Financial Performance - In Q1 2025, the company reported a main revenue of 502 million yuan, a year-on-year increase of 3.97% [11] - The net profit attributable to shareholders was 7.13 million yuan, reflecting a significant year-on-year increase of 93.95% [11] - The company maintained a debt ratio of 11.74% and a gross profit margin of 6.52% [11]

Group 1: Company Development Strategy - The company focuses on high-quality development, emphasizing the production of petroleum resins and polypropylene, while enhancing the industrial chain and core competitiveness [1] - The company promotes new technologies and innovations to drive high-end, intelligent, and green development, effectively integrating raw material resources [1] Group 2: Shareholder and Market Management - The controlling shareholder implements market value management as part of performance evaluation, with key indicators including stock price comparison, comprehensive index comparison, and investor relations metrics [1] - There is no industry competition between the controlling shareholder and the company [2] Group 3: Research and Development Adjustments - The company optimized its R&D projects based on market trends and customer feedback, leading to a significant change in R&D personnel, with 6 dedicated staff in the new planning project department [2] - The company has paused some R&D projects to focus on new product development [2] Group 4: Impact of Policies and Raw Material Supply - The company is not significantly affected by the "anti-involution" policy, as it relies on stable raw material supplies from its main supplier [2] - The company aims to enhance operational efficiency and profitability through technological innovation and product quality improvement [2] Group 5: New Energy and New Materials Initiatives - In 2024, the company established a 10,800 tons/year butadiene extraction facility, which began production in October 2024 [3] - A project to upgrade the isoprene hydrogenation facility is planned for 2025, increasing capacity to 35,000 tons/year [3] - These projects are expected to significantly enhance the company's profitability [3]

Core Points - Daqing Huake Co., Ltd. is in the process of transferring part of its pharmaceutical division's assets, with previous announcements made on December 21, 2024, and May 28, 2025 [1] - The company attempted to sell machinery and equipment assets valued at 11.83 million yuan (excluding VAT) but failed to attract any buyers during the initial listing period [1] - The company subsequently reduced the asking price to 10.65 million yuan, which is 90% of the assessed value, but again did not find any qualified buyers, leading to the termination of the asset transfer process [1][2] Future Actions - The company will continue to seek potential buyers and will re-initiate the asset transaction approval process and related disclosures when the timing is appropriate [2]

Core Viewpoint - Daqing Huake Co., Ltd. has announced its profit distribution plan for the year 2024, which includes a cash dividend of 0.50 RMB per 10 shares, totaling 6,481,975 RMB, to be distributed to shareholders [1][2]. Summary by Sections Profit Distribution Plan - The profit distribution plan was approved at the shareholders' meeting held on May 21, 2025, with a cash dividend of 0.50 RMB per 10 shares (including tax) [1]. - The total cash dividend amounts to 6,481,975 RMB (including tax), with the remaining undistributed profits carried forward to the next year [1]. Dividend Distribution Details - The distribution is based on the current total share capital of 129,639,500 shares, with adjustments made if there are changes in total share capital due to share buybacks or new issuances [1]. - For foreign institutions and certain individual shareholders, the cash dividend will be 0.45 RMB per 10 shares after tax [1]. Taxation Information - The company will not withhold individual income tax at the time of distribution; instead, tax will be calculated based on the holding period when shares are sold [1]. - Different tax rates apply for various categories of shareholders, with specific rates outlined for different holding periods [1]. Key Dates - The record date for the distribution is June 19, 2025, and the ex-dividend date is June 20, 2025 [1][2]. Distribution Method - Cash dividends will be directly credited to the shareholders' accounts through their securities companies on the ex-dividend date [2]. - The company assumes all legal responsibilities for any shortfall in cash dividends due to a decrease in shares held by shareholders during the distribution application period [2].

证券代码：000985 证券简称：大庆华科 公告编号：2025016 大庆华科股份有限公司 2024年年度权益分派实施公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 大庆华科股份有限公司（以下简称"公司"）2024年年度利润分配 方案已获2025年5月21日召开的公司2024年年度股东大会审议通过，现 将权益分派事宜公告如下： 2、自分配方案披露至实施期间公司总股本未发生变化。若在该方 案实施前，公司总股本由于股份回购、发行新股等原因而发生变动的， 分配将按"分派总额固定不变"的原则相应调整。 3、本次实施的分配方案与股东大会审议通过的分配方案一致。 4、本次实施的分配方案距离股东大会审议通过的时间未超过两个 月。 二、权益分派方案 公司2024年年度权益分派方案为：以公司现有总股本129,639,500 股为基数，向全体股东每10股派0.50元人民币现金（含税；扣税后，境 外机构（含QFII、RQFII）以及持有首发前限售股的个人和证券投资基 金每10股派0.45元；持有首发后限售股、股权激励限售股及无限售流通 股的个人股息红利税实行差别化税率征收，本 ...

证券代码：000985 证券简称：大庆华科 公告编号：2025017 大庆华科股份有限公司 关于转让药业分公司部分资产的进展公告 特此公告。 大庆华科股份有限公司董事会 2025年5月11日 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假记 载、误导性陈述或重大遗漏。 大庆华科股份有限公司（以下简称"公司"）分别于2024年12月 21日、2025年5月28日在《中国证券报》《上海证券报》及巨潮资讯网 （www.cninfo.com.cn）披露了《关于转让药业分公司部分资产的公 告》（公告编号2024034）、《关于转让药业分公司部分资产的进展公告》 （公告编号2025015），部分资产转让进展情况如下： 2025年4月8日，药业分公司机器设备资产在武汉光谷联合产权交 易所以评估值1,183.51万元（不含增值税）为底价挂牌交易，因在规 定期限内无意向购买方摘牌，根据《企业国有资产交易监督管理办法》 （国务院国资委、财政部令第32号）的相关规定，公司于2025年5月 26日将药业分公司机器设备资产底价降至评估价的90%，以1,065.16 万元再次挂牌交易，在公开挂牌期限届满未征集到符合条 ...

证券代码：000985 证券简称：大庆华科 公告编号：2025015 大庆华科股份有限公司 关于转让药业分公司部分资产的进展公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整， 没有虚假记载、误导性陈述或重大遗漏。 大庆华科股份有限公司（以下简称"公司"）于2024年12月21日 在《中国证券报》《上海证券报》及巨潮资讯网（www.cninfo.com.cn） 披露了《关于转让药业分公司部分资产的公告》（公告编号2024034）， 进展情况如下： 一、药业分公司机器设备资产挂牌交易 2025年4月8日，药业分公司机器设备资产在武汉光谷联合产权交 易所以评估值1,183.51万元（不含增值税）为底价挂牌交易，挂牌日 期截至2025年5月7日，在规定期限内无意向购买方摘牌。 根据《企业国有资产交易监督管理办法》（国务院国资委、财政 部令第32号）的相关规定，公司决定将药业分公司机器设备资产底价 降至评估价的90%，以1,065.16万元再次在武汉光谷联合产权交易所 挂牌，挂牌日期自2025年5月26日至2025年6月9日。 （一）购买方（受让方）及出售方（出让方） 受让方：大庆高新技术产业开发区运行保 ...

Core Viewpoint - The legal opinion letter confirms the legality of the 2024 annual general meeting of Daqing Huake Co., Ltd., including the procedures for convening and holding the meeting, the qualifications of attendees, and the voting process for the resolutions presented [1][4][8]. Group 1: Meeting Procedures - The annual general meeting was proposed and convened by the board of directors, with the meeting scheduled for May 21, 2025, following a board meeting on April 24, 2025 [2][3]. - The notice for the meeting was published on April 26, 2025, detailing the time, location, and agenda, with a reminder notice issued on May 17, 2025 [2][3]. - The meeting was held on May 21, 2025, at 14:30, in Daqing, Heilongjiang Province, and was presided over by the chairman [3][4]. Group 2: Attendee Qualifications - A total of three shareholders and their proxies attended the meeting, representing 82,320,800 shares, which is a significant portion of the company's total shares [4][5]. - The qualifications of the attending shareholders and proxies were verified as compliant with legal requirements [4][5]. Group 3: Voting Results - The meeting included eight proposals, with the first proposal regarding the 2024 board work report receiving 82,488,600 votes in favor, representing 99.8667% of the votes cast [5][6]. - The second proposal concerning the 2024 supervisory board work report also passed with 82,488,100 votes in favor, equating to 99.8661% [6][7]. - The financial resolutions, including the 2024 financial settlement and 2025 budget, were approved with similar overwhelming support, indicating strong shareholder confidence [6][7][8].

证券代码：000985 证券简称：大庆华科 公告编号：2025014 大庆华科股份有限公司 2024 年年度股东大会决议公告 （2）网络投票时间：通过深圳证券交易所交易系统进行网络投 票的具体时间为：2025 年 5 月 21 日 9:15—9:25，9:30—11:30 和 13:00—15:00。 通过深圳证券交易所互联网投票系统进行网络投票的具体时间 为：2025 年 5 月 21 日 9:15--15:00。 2、会议召开地点：大庆市龙凤区兴化北街 8 号公司办公楼一楼 会议室。 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或者重大遗漏。 特别提示： 1、本次股东大会没有出现否决提案的情形。 2、本次股东大会不涉及变更以往股东大会已通过的决议。 一、会议召开和出席情况 1、会议召开时间 （1）现场会议召开时间：2025 年 5 月 21 日（星期三）14:30。 3、召开方式：现场投票与网络投票相结合的方式。 4、召集人：公司董事会。 5、主持人：王洪涛先生。 6、本次会议的召集、召开及表决方式符合《公司法》《上市公司 — 1 — 股东大会规则》《深圳证券交易所 ...